Literature DB >> 30514365

Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation.

Mohammad Shafiul Alam1, Mohammad Golam Kibria1, Nusrat Jahan1, Ric N Price2,3, Benedikt Ley4.   

Abstract

OBJECTIVES: Spectrophotometry kits from Pointe Scientific (PS; USA) were compared to kits from Trinity Biotech (Trinity; Ireland) in 50 venous blood samples from purposively selected individuals in Bangladesh. Repeatability and inter-assay variability were assessed by Students t-test, Bland-Altman plot and Pearson correlation coefficient (r). The median glucose-6-phosphate dehydrogenase (G6PD) activity of all G6PD normal participants was calculated per assay and defined as 100% activity. Performance was calculated considering 30% and 70% cut off activities and Trinity as reference.
RESULTS: The intra-assay correlation of Trinity (r = 0.9841, p < 0.001) and PS (r = 0.9833, p < 0.001) did not differ significantly (p = 0.904). Both assays were closely correlated (r = 0.9799, p < 0.001), with a mean difference of 0.1 U/gHb (95% limit of agreement: - 1.32 to 1.57). At 30% cut off PS had a sensitivity of 100% (95% confidence interval (95 CI) 59.0-100.0) and specificity of 100% (95% CI 91.8 to 100.0), at 70% cut-off of 100% (95% CI 79.4-100.0) and 97.1% (95% CI 84.7-99.9) respectively. The G6PD assay from PS is a reliable alternative to the assay from Trinity.

Entities:  

Keywords:  G6PD; Malaria; Spectrophotometry

Mesh:

Substances:

Year:  2018        PMID: 30514365      PMCID: PMC6278131          DOI: 10.1186/s13104-018-3964-7

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


Introduction

Glucose-6-phosphate dehydrogenase (G6PD) is the rate limiting step of the pentose-phosphate-pathway (PPP), which reduces nicotinamide adenine dinucleotide phosphate (NADP+) to nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) [1]. G6PD deficiency is the most common enzymopathy worldwide, affecting approximately 400 million people globally [2]. G6PD deficiency does not affect life expectancy in most cases it is however a known risk factor for hyperbilirubinemia and kernicterus [3] and can result in hemolysis induced by specific compounds such as fava beans, sulphonamides, quinolones, dapsone and the 8-aminoquinoline class of antimalarials [2]. The reference method for the quantification of G6PD enzyme activity is spectrophotometry [4-6], a method based on the colorimetric detection of NADPH. In brief a defined amount of hemolysate is added to a solution containing glucose-6-phosphate and NADP, which results in the formation of NADPH facilitated through G6PD. Depending on the activity of the G6PD, NADPH production varies and can be measured at a wavelength of 340 nm over a predefined time interval at standardized temperatures [7]. There are a number of spectrophotometry kits from different providers available, one of the most common is that manufactured by Trinity Biotech (Trinity; Ireland). In 2017 the company suspended their production due to difficulties in maintaining quality standards for their reagents. Pointe Scientific (PS; USA) also produce reagents for G6PD spectrophotometry that are similar to Trinity in their operational characteristics, however are designed for a higher optimal measuring temperature. The aim of this study was to compare the intra and inter assay variability derived from spectrophotometry using reagents from Trinity and PS.

Main text

Methods

Venous blood (total 3 mL) was collected from purposively selected participants with known G6PD activity in the Chittagong Hill Tracts, Bangladesh to cover the broadest possible range of G6PD activities. Samples were stored at 4 °C and G6PD activity measured within 24 h by spectrophotometry in a reference laboratory in Dhaka. Haemoglobin (Hb) was measured by a complete blood count (CBC) using a XN-1000 (Sysmex Corporation, Kobe, Japan) immediately before spectrophotometry; samples were tested no more than an hour apart on a Shimadzu UV-1800 (Shimadzu, Japan) with kits from Trinity (Cat. No.: 345-B) and PS (Cat. No.: G7583) according to manufacturer instructions. Each kit was run in duplicate, with a measuring temperature of 30 °C for Trinity and 37 °C for PS, all measurements were done by the same two experienced and well-trained laboratory technicians who had a Master degree in a relevant field. G6PD activity was calculated from the change in absorbance at 340 nm over a period of 5 min, as per the manufacturer’s instructions, and the derived G6PD activity (U/dL) was normalized by Hb (U/gHb). G6PD deficient (Cat. No.: HC-108DE), intermediate (Cat. No.: HC-108IN) and normal controls (Cat. No.: HCS-108) (all from ACS Inc., Fishers, USA) were run daily prior to sample testing. Repeatability was assessed per assay by correlating the first and second measurement of each kit. For the inter-assay comparison, the mean of both normalized results was calculated and compared by Students t-test, Bland Altman plots and the Pearson correlation coefficient (r). 100% G6PD activity was defined for each assay by calculating the median activity of all participants that had been found to have G6PD activity above 70% of the adjusted male median (AMM) in earlier studies [4, 8]. Each individual was then categorized as having below 10%, below 30% and below 70% activity. The proportions within each category were compared between kits using the McNemars test for correlated proportions. The sensitivity and specificity of PS were calculated at each threshold assuming Trinity as the gold standard assay [4].

Results

A total of 50 samples were analysed by both kits and no results were excluded from the analysis. The repeatability of Trinity (r = 0.9841, p < 0.001) and PS (r = 0.9833, p < 0.001) was very high and did not differ significantly among the assays (p = 0.904). The results from PS correlated closely with results from Trinity (r = 0.9799, p < 0.001; Fig. 1). The mean of the activities derived by Trinity was 7.6 U/gHb (95% confidence interval (95% CI) 6.53–8.64) compared to 7.7 U/gHb (95% CI 6.67–8.75) derived by PS; p = 0.126), with 95% limits of agreement ranging from − 1.32 to 1.57 U/gHb.
Fig. 1

Scatter plot mean Trinity Biotech (Trinity) results vs. mean Pointe Scientific (PS) results. Red lines from origin outwards indicate 10%, 30%, 70% and 100% cut off activity

Scatter plot mean Trinity Biotech (Trinity) results vs. mean Pointe Scientific (PS) results. Red lines from origin outwards indicate 10%, 30%, 70% and 100% cut off activity 100% G6PD activity was based on 24 samples and was 10.1 U/gHb (interquartile range (IQR): 8.98–11.24) for PS and 9.6 U/gHb (IQR: 8.88–11.04) for Trinity. When results were categorized, 1 discrepant result (2%) was observed (Table 1 and Fig. 1), and the proportion of samples classified as being below 30% and 70% did not differ significantly (p = 1.000 and p = 0.317 respectively). At the 30% threshold the sensitivity of PS was 100% (95% CI 59.0–100.0) with a specificity of 100% (95% CI 91.8 to 100.0), at the 70% threshold the corresponding values were 100% (95% CI 79.4–100.0) and 97.1% (95% CI 84.7–99.9) respectively.
Table 1

Distribution of categorized result / test kits

Trinity
Pointe Scientific < 10%a10% to < 30%a30% to < 70%a> 70%aTotal
< 10%b20002
10% to < 30%b15005
30% to < 70%b009110
> 70%b0003333
Total2593450

a 100% G6PD activity Trinity: 9.6 U/gHb

b 100% G6PD activity Pointe Scientific: 10.1 U/gHb

Distribution of categorized result / test kits a 100% G6PD activity Trinity: 9.6 U/gHb b 100% G6PD activity Pointe Scientific: 10.1 U/gHb

Discussion

These findings demonstrate that PS is a reliable alternative to the assays from Trinity for the quantification of G6PD enzyme activity by spectrophotometry. Intra and inter assay correlation for the assays was excellent, suggesting that a single measurement would be sufficient providing good quality control and well-informed technicians. No sample with G6PD activity below the clinically relevant 30% cut off activity was misclassified, one sample was considered below 70% by PS but not by Trinity [9], however the respective sample was borderline (Fig. 1). Both assays showed a very small mean difference, suggesting that population specific cut offs [4] established earlier by Trinity kits are likely to be applicable to results obtained using the PS kits, although further confirmatory studies are warranted. The operational characteristics of both assays are similar, with the exception that PS requires a higher temperature if no temperature correction factor is to be applied. This minor modification can be achieved on most if not all spectrophotometers suitable for Trinity kits. The cost of the Trinity kit in 2016 was 3.60 USD/test, whereas the cost of each PS kit is currently approximately 2.00 USD/test (these prices refer to the Australian market and are likely to differ depending on location and distributor).

Conclusion

These results demonstrate that both assays work well if performed by well trained technicians and when maintaining quality control measures. Given that assays from Trinity are no longer available, assays from PS provide a good alternative at lower costs.

Limitations

All samples were tested on a high—end machine, assays may perform at lower accuracy on different machines. Inter-reader variability was not assessed in the course of this study, however given the consistent results, good performance observed and extensive experiences of both laboratory technicians we do not believe this has impacted on our findings. Additional file 1. Database with all relevant information
  9 in total

Review 1.  Managing the jaundiced newborn: a persistent challenge.

Authors:  M Jeffrey Maisels
Journal:  CMAJ       Date:  2014-11-10       Impact factor: 8.262

Review 2.  Standardization of procedures for the study of glucose-6-phosphate dehydrogenase. Report of a WHO Scientific Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1967

Review 3.  Glucose-6-phosphate dehydrogenase deficiency.

Authors:  M D Cappellini; G Fiorelli
Journal:  Lancet       Date:  2008-01-05       Impact factor: 79.321

Review 4.  Glucose-6-phosphate dehydrogenase laboratory assay: How, when, and why?

Authors:  Angelo Minucci; Bruno Giardina; Cecilia Zuppi; Ettore Capoluongo
Journal:  IUBMB Life       Date:  2009-01       Impact factor: 3.885

Review 5.  Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report.

Authors:  Lorenz von Seidlein; Sarah Auburn; Fe Espino; Dennis Shanks; Qin Cheng; James McCarthy; Kevin Baird; Catherine Moyes; Rosalind Howes; Didier Ménard; Germana Bancone; Ari Winasti-Satyahraha; Lasse S Vestergaard; Justin Green; Gonzalo Domingo; Shunmay Yeung; Ric Price
Journal:  Malar J       Date:  2013-03-27       Impact factor: 2.979

6.  A Comparison of Three Quantitative Methods to Estimate G6PD Activity in the Chittagong Hill Tracts, Bangladesh.

Authors:  Benedikt Ley; Mohammad Shafiul Alam; James J O'Donnell; Mohammad Sharif Hossain; Mohammad Golam Kibria; Nusrat Jahan; Wasif A Khan; Kamala Thriemer; Mark D Chatfield; Ric N Price; Jack S Richards
Journal:  PLoS One       Date:  2017-01-25       Impact factor: 3.240

7.  Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.

Authors:  James Watson; Walter R J Taylor; Germana Bancone; Cindy S Chu; Podjanee Jittamala; Nicholas J White
Journal:  PLoS Negl Trop Dis       Date:  2018-04-20

8.  G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests.

Authors:  Gonzalo J Domingo; Ari Winasti Satyagraha; Anup Anvikar; Kevin Baird; Germana Bancone; Pooja Bansil; Nick Carter; Qin Cheng; Janice Culpepper; Chi Eziefula; Mark Fukuda; Justin Green; Jimee Hwang; Marcus Lacerda; Sarah McGray; Didier Menard; Francois Nosten; Issarang Nuchprayoon; Nwe Nwe Oo; Pongwit Bualombai; Wadchara Pumpradit; Kun Qian; Judith Recht; Arantxa Roca; Wichai Satimai; Siv Sovannaroth; Lasse S Vestergaard; Lorenz Von Seidlein
Journal:  Malar J       Date:  2013-11-04       Impact factor: 2.979

Review 9.  Methods for the field evaluation of quantitative G6PD diagnostics: a review.

Authors:  Benedikt Ley; Germana Bancone; Lorenz von Seidlein; Kamala Thriemer; Jack S Richards; Gonzalo J Domingo; Ric N Price
Journal:  Malar J       Date:  2017-09-11       Impact factor: 2.979

  9 in total
  7 in total

1.  Case Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh.

Authors:  Ching Swe Phru; Mohammad Golam Kibria; Kamala Thriemer; Mahtab Uddin Chowdhury; Nusrat Jahan; M M Aktaruzzaman; Hisni Rahmat; Ari Winasti Satyagraha; Aung Swi Prue; Wasif Ali Khan; Benedikt Ley; Mohammad Shafiul Alam
Journal:  Am J Trop Med Hyg       Date:  2020-01       Impact factor: 2.345

Review 2.  Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency.

Authors:  Kaitlyn Ryan; Babu L Tekwani
Journal:  Pharmacol Ther       Date:  2020-12-14       Impact factor: 13.400

3.  Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis.

Authors:  Daniel A Pfeffer; Benedikt Ley; Rosalind E Howes; Patrick Adu; Mohammad Shafiul Alam; Pooja Bansil; Yap Boum; Marcelo Brito; Pimlak Charoenkwan; Archie Clements; Liwang Cui; Zeshuai Deng; Ochaka Julie Egesie; Fe Esperanza Espino; Michael E von Fricken; Muzamil Mahdi Abdel Hamid; Yongshu He; Gisela Henriques; Wasif Ali Khan; Nimol Khim; Saorin Kim; Marcus Lacerda; Chanthap Lon; Asrat Hailu Mekuria; Didier Menard; Wuelton Monteiro; François Nosten; Nwe Nwe Oo; Sampa Pal; Duangdao Palasuwan; Sunil Parikh; Ayodhia Pitaloka Pasaribu; Jeanne Rini Poespoprodjo; David J Price; Arantxa Roca-Feltrer; Michelle E Roh; David L Saunders; Michele D Spring; Inge Sutanto; Kamala Ley-Thriemer; Thomas A Weppelmann; Lorenz von Seidlein; Ari Winasti Satyagraha; Germana Bancone; Gonzalo J Domingo; Ric N Price
Journal:  PLoS Med       Date:  2020-05-14       Impact factor: 11.069

4.  Repeatability and reproducibility of a handheld quantitative G6PD diagnostic.

Authors:  Benedikt Ley; Ari Winasti Satyagraha; Mohammad Golam Kibria; Jillian Armstrong; Germana Bancone; Amy K Bei; Greg Bizilj; Marcelo Brito; Xavier C Ding; Gonzalo J Domingo; Michael E von Fricken; Gornpan Gornsawun; Brandon Lam; Didier Menard; Wuelton Monteiro; Stefano Ongarello; Sampa Pal; Lydia Visita Panggalo; Sunil Parikh; Daniel A Pfeffer; Ric N Price; Alessandra da Silva Orfano; Martina Wade; Mariusz Wojnarski; Kuntawunginn Worachet; Aqsa Yar; Mohammad Shafiul Alam; Rosalind E Howes
Journal:  PLoS Negl Trop Dis       Date:  2022-02-17

5.  Evaluation of strategies for identification of infants with pathogenic glucose-6-phosphate dehydrogenase variants in China.

Authors:  Zhongmin Xia; Xudong Wang; Huiming Ye; Chunliu Gao; Xiaoman Zhou; Jing Chen; Yunsheng Ge; Juan Li; Yulin Zhou; Qiwei Guo
Journal:  Front Genet       Date:  2022-09-23       Impact factor: 4.772

6.  Vivax malaria in pregnancy and lactation: a long way to health equity.

Authors:  Tobias Brummaier; Mary Ellen Gilder; Gornpan Gornsawun; Cindy S Chu; Germana Bancone; Mupawjay Pimanpanarak; Kesinee Chotivanich; François Nosten; Rose McGready
Journal:  Malar J       Date:  2020-01-22       Impact factor: 2.979

7.  Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis.

Authors:  Benedikt Ley; Ari Winasti Satyagraha; Hisni Rahmat; Michael E von Fricken; Nicholas M Douglas; Daniel A Pfeffer; Fe Espino; Lorenz von Seidlein; Gisela Henriques; Nwe Nwe Oo; Didier Menard; Sunil Parikh; Germana Bancone; Amalia Karahalios; Ric N Price
Journal:  PLoS Med       Date:  2019-12-13       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.